CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Commercial feasibility of microbial therapy

Cel

Our body is colonized by complex microbial communities (our microbiome) that are most abundant in the intestinal tract where they contribute significantly to our health and disease. It has been established that aberrations in our microbiome are of particular importance in obesity, type 2 diabetes and metabolic syndrome, rapidly growing diseases with a drug market volume of over 5 B$ per year. We have discovered in the ERC project Microbes Inside that a particular bacterium is able to modify the intestinal microbiome and may be used to develop a new approach to treat these and other metabolic diseases. The Proof of Concept project ACOM aims to confirm the commercial and technological feasibility of this approach, consolidate and expand our IP position, and develop a product development plan. These form the elements of a business plan that is expected to result in establishing a spin out company (ACOM).

Zaproszenie do składania wniosków

ERC-2013-PoC
Zobacz inne projekty w ramach tego zaproszenia

Instytucja przyjmująca

WAGENINGEN UNIVERSITY
Wkład UE
€ 142 000,00
Adres
DROEVENDAALSESTEEG 4
6708 PB Wageningen
Niderlandy

Zobacz na mapie

Region
Oost-Nederland Gelderland Veluwe
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Tom Bessems (Mr.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)